Association of IL-6 polymorphisms with hepatocellular carcinoma risk: Evidences from a meta-analysis

Tumor Biology

Volumn 35, Issue 4, 2014, Pages 3551-3561

  Liu, Ying ^a   Gao, Su Jun ^b   Du, Bo Xiang ^c   Wang, Jie Jun ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b NORTHERN JIANGSU PEOPLE S HOSPITAL   (China)

^c NANTONG UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; Interleukin 6; Meta analysis; Polymorphism

Indexed keywords

INTERLEUKIN 6;

ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CONFIDENCE INTERVAL; DISEASE ASSOCIATION; ETHNICITY; GENETIC MODEL; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENOTYPE; HEPATITIS B VIRUS; HUMAN; INFLAMMATION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; VIRUS CARRIER;

CARCINOMA, HEPATOCELLULAR; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTERLEUKIN-6; LIVER NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PUBLICATION BIAS;

EID: 84898798664     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1469-5     Document Type: Article

References (46)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132(7):2557-76.
2. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362(9399):1907-17.
3. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004;127(5 Suppl 1):S5-S16.
4. Parikh S, Hyman D. Hepatocellular cancer: a guide for the internist. Am J Med. 2007;120(3):194-202.
5. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127(5 Suppl 1):S35-50.
6. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860-7.
7. Alison MR, Nicholson LJ, Lin WR. Chronic inflammation and hepatocellular carcinoma. Recent Results Cancer Res. 2011;185:135-48.
8. Levrero M. Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene. 2006;25(27):3834-47.
9. Elsharkawy AM, Mann DA. Nuclear factor-kappaB and the hepatic inflammation-fibrosis-cancer axis. Hepatology. 2007;46(2):590-7.
10. Oyanagi Y, Takahashi T, Matsui S, Takahashi S, Boku S, Takahashi K, et al. Enhanced expression of interleukin-6 in chronic hepatitis C. Liver. 1999;19(6):464-72.
11. Naugler WE, Karin M. The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med. 2008;14(3):109-19.
12. Soresi M, Giannitrapani L, D'Antona F, Florena AM, La Spada E, Terranova A, et al. Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma. World J Gastroenterol. 2006;12(16):2563-8.
13. Porta C, De Amici M, Quaglini S, Paglino C, Tagliani F, Boncimino A, et al. Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma. Annals Oncol. 2008;19(2):353-8.
14. Wong VW, Yu J, Cheng AS, Wong GL, Chan HY, Chu ES, et al. High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B. Int J Cancer. 2009;124(12):2766-70.
15. Hirano T. Interleukin 6 and its receptor: ten years later. Int Rev Immunol. 1998;16(3-4):249-84.
16. Basso D, Scrigner M, Toma A, Navaglia F, Di Mario F, Rugge M, et al. Helicobacter pylori infection enhances mucosal interleukin-1 beta, interleukin-6, and the soluble receptor of interleukin-2. Int J Clin Lab Res. 1996;26(3):207-10.
17. Terry CF, Loukaci V, Green FR. Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J Biol Chem. 2000;275(24):18138-44.
18. Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest. 1998;102(7):1369-76.
19. Hefler LA, Grimm C, Ackermann S, Malur S, Radjabi-Rahat AR, Leodolter S, et al. An interleukin-6 gene promoter polymorphism influences the biological phenotype of ovarian cancer. Cancer Res. 2003;63(12):3066-8.
20. Olomolaiye O, Wood NA, Bidwell JL. A novel NlaIII polymorphism in the human IL-6 promoter. Eur J Immunogenet. 1998;25(2-3):267.
21. Yang Z, Liang Y, Qin B, Zhong R. A meta-analysis of the association of IL-6-174 G/C and -572 G/C polymorphisms with systemic lupus erythematosus risk. Rheumatol Int. 2013, doi: 10.1007/s00296-013-2855-4.
22. Yang Y, Zhang F, Skrip L, Lei H, Wang Y, Hu D, et al. IL-6 gene polymorphisms and CAD risk: a meta-analysis. Mol Biol Rep. 2013;40(3):2589-98.
23. Sfrent-Cornateanu R, Mihai C, Balan S, Ionescu R, Moldoveanu E. The IL-6 promoter polymorphism is associated with disease activity and disability in systemic sclerosis. J Cell Mol Med. 2006;10(4):955-9.
24. Belluco C, Olivieri F, Bonafe M, Giovagnetti S, Mammano E, Scalerta R, et al. 174 G>C polymorphism of interleukin 6 gene promoter affects interleukin 6 serum level in patients with colorectal cancer. Clin Cancer Res. 2003;9(6):2173-6.
25. Qi L, van Dam RM, Meigs JB, Manson JE, Hunter D, Hu FB. Genetic variation in IL6 gene and type 2 diabetes: tagging-SNP haplotype analysis in large-scale case-control study and meta-analysis. Hum Mol Genet. 2006;15(11):1914-20.
26. Jiang RQ, Deng L, Zhao L, Li XC, Zhang F, Xia YX, et al. miR-22 promotes HBV-related hepatocellular carcinoma development in males. Clin Cancer Res. 2011;17(17):5593-603.
27. Jain S, Li Y, Patil S, Kumar A. A single-nucleotide polymorphism in human angiotensinogen gene is associated with essential hypertension and affects glucocorticoid induced promoter activity. J Mol Med (Berl). 2005;83(2):121-31.
28. Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney AM. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem. 1993;268(15):10739-45.
29. Cussigh A, Falleti E, Fabris C, Bitetto D, Cmet S, Fontanini E, et al. Interleukin 6 promoter polymorphisms influence the outcome of chronic hepatitis C. Immunogenetics. 2011;63(1):33-41.
30. Minton EJ, Smillie D, Smith P, Shipley S, McKendrick MW, Gleeson DC, et al. Clearance of hepatitis C virus is not associated with single nucleotide polymorphisms in the IL-1,-6, or-10 genes. Hum Immunol. 2005;66(2):127-32.
31. Falleti E, Fabris C, Vandelli C, Colletta C, Cussigh A, Smirne C, et al. Genetic polymorphisms of interleukin-6 modulate fibrosis progression in mild chronic hepatitis C. Hum Immunol. 2010;71(10):999-1004.
32. Saxena R, Chawla YK, Kaur J. Association of IL-6 gene polymorphism and its levels in HBV related hepatocellular carcinoma progression in India. Int J Infect Dis. 2011;15:S75-6.
33. Giannitrapani L, Soresi M, Giacalone A, Campagna ME, Marasa M, Cervello M, et al. IL-6-174G/C polymorphism and IL-6 serum levels in patients with liver cirrhosis and hepatocellular carcinoma. OMICS. 2011;15(3):183-6.
34. Ognjanovic S, Yuan JM, Chaptman AK, Fan Y, Yu MC. Genetic polymorphisms in the cytokine genes and risk of hepatocellular carcinoma in low-risk non-Asians of USA. Carcinogenesis. 2009;30(5):758-62.
35. Falleti E, Fabris C, Toniutto P, Fontanini E, Cussigh A, Bitetto D, et al. Interleukin-6 polymorphisms and gender: relationship with the occurrence of hepatocellular carcinoma in patients with end-stage liver disease. Oncology. 2009;77(5):304-13.
36. Migita K, Miyazoe S, Maeda Y, Daikoku M, Abiru S, Ueki T, et al. Cytokine gene polymorphisms in Japanese patients with hepatitis B virus infection - association between TGF-beta1 polymorphisms and hepatocellular carcinoma. J Hepatol. 2005;42(4):505-10.
37. Ben-Ari Z, Mor E, Papo O, Kfir B, Sulkes J, Tambur AR, et al. Cytokine gene polymorphisms in patients infected with hepatitis B virus. Am J Gastroenterol. 2003;98(1):144-50.
38. Liu S, Qiu XQ, Zeng XY, Bai H, Bei CH, Yang Y. Relationship between IL6-572G/C polymorphism and hepatocellular carcinoma in men. Zhonghua Gan Zang Bing Za Zhi. 2012;20(6):463-7.
39. Qiu XQ, Bei CH, Yu HP, Zeng XY, Zhong QA. Study on the relationship between single-nucleotide polymorphisms in IL-6, IL-10 genes and HBV-related hepatocellular carcinoma. Zhonghua Liu Xing Bing Xue Za Zhi. 2011;32(5):510-3.
40. Park BL, Lee HS, Kim YJ, Kim JY, Jung JH, Kim LH, et al. Association between interleukin 6 promoter variants and chronic hepatitis B progression. Exp Mol Med. 2003;35(2):76-82.
41. Bennermo M, Held C, Stemme S, Ericsson CG, Silveira A, Green F, et al. Genetic predisposition of the interleukin-6 response to inflammation: implications for a variety of major diseases? Clin Chem. 2004;50(11):2136-40.
42. Cox ED, Hoffmann SC, DiMercurio BS, Wesley RA, Harlan DM, Kirk AD, et al. Cytokine polymorphic analyses indicate ethnic differences in the allelic distribution of interleukin-2 and interleukin-6. Transplantation. 2001;72(4):720-6.
43. Jerrard-Dunne P, Sitzer M, Risley P, Buehler A, von Kegler S, Markus HS. Inflammatory gene load is associated with enhanced inflammation and early carotid atherosclerosis in smokers. Stroke. 2004;35(11):2438-44.
44. Xu B, Niu XB, Wang ZD, Cheng W, Tong N, Mi YY, et al. IL-6-174G>C polymorphism and cancer risk: a meta-analysis involving 29,377 cases and 37,739 controls. Mol Biol Rep. 2011;38(4):2589-96.
45. Wang J, He W, Liu J, Nong L, Wei Y, Yang F. Association of IL-6 polymorphisms with gastric cancer risk: evidences from a meta-analysis. Cytokine. 2012;59(1):176-83.
46. Yin YW, Sun QQ, Hu AM, Wang Q, Liu HL, Hou ZZ, et al. Associations between interleukin-6 gene -174 C/G and -572 C/G polymorphisms and the risk of gastric cancer: a meta-analysis. J Surg Oncol. 2012;106(8):987-93.